The top 10 largest biopharma M&A deals in 2020

The top 10 largest biopharma M&A deals in 2020

Source: 
Fierce Pharma
snippet: 

Biopharma M&A activities suffered a slowdown in 2020. One could argue that 2019’s megadeals consumed some of last year’s quota, and COVID-19 definitely didn’t help. But AstraZeneca’s $39 billion deal for Alexion Pharmaceutical and Gilead’s $21 billion acquisition of Immunomedics showed the appetite for dealmaking is still there.